| Drug-Target Information | ||||||||
|---|---|---|---|---|---|---|---|---|
| Drug Name | Target Name | Drug Type | Target Type | Source | Drug MeSHID | Interaction Score | Drug Status | Target Action |
| lenvatinib | fibroblast growth factor receptor 1 | small molecule | NA | drugbank , DGIDB | Thyroid Gland[MeSHID:D013961] Disease[MeSHID:D004194] Radioactivity[MeSHID:D011851] Renal Cell Carcinoma[MeSHID:D002292] Thyroid carcinoma[MeSHID:D013964] Neoplasm Metastasis[MeSHID:D009362] Cell Differentiation process[MeSHID:D002454] Liver carcinoma[MeSHID:D006528] Recurrence (disease attribute)[MeSHID:D012008] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] melanoma[MeSHID:D008545] Malignant Neoplasms[MeSHID:D009369] Malignant neoplasm of ovary[MeSHID:D010051] Non-Small Cell Lung Carcinoma[MeSHID:D002289] |
0.24 | approved,investigational | inhibitor |
| lenvatinib | fibroblast growth factor receptor 2 | small molecule | NA | drugbank , DGIDB | Thyroid Gland[MeSHID:D013961] Disease[MeSHID:D004194] Radioactivity[MeSHID:D011851] Renal Cell Carcinoma[MeSHID:D002292] Thyroid carcinoma[MeSHID:D013964] Neoplasm Metastasis[MeSHID:D009362] Cell Differentiation process[MeSHID:D002454] Liver carcinoma[MeSHID:D006528] Recurrence (disease attribute)[MeSHID:D012008] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] melanoma[MeSHID:D008545] Malignant Neoplasms[MeSHID:D009369] Malignant neoplasm of ovary[MeSHID:D010051] Non-Small Cell Lung Carcinoma[MeSHID:D002289] |
0.21 | approved,investigational | inhibitor |
| lenvatinib | fibroblast growth factor receptor 3 | small molecule | NA | drugbank | Thyroid Gland[MeSHID:D013961] Disease[MeSHID:D004194] Radioactivity[MeSHID:D011851] Renal Cell Carcinoma[MeSHID:D002292] Thyroid carcinoma[MeSHID:D013964] Neoplasm Metastasis[MeSHID:D009362] Cell Differentiation process[MeSHID:D002454] Liver carcinoma[MeSHID:D006528] Recurrence (disease attribute)[MeSHID:D012008] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] melanoma[MeSHID:D008545] Malignant Neoplasms[MeSHID:D009369] Malignant neoplasm of ovary[MeSHID:D010051] Non-Small Cell Lung Carcinoma[MeSHID:D002289] |
NA | approved,investigational | inhibitor |
| lenvatinib | fibroblast growth factor receptor 4 | small molecule | NA | drugbank | Thyroid Gland[MeSHID:D013961] Disease[MeSHID:D004194] Radioactivity[MeSHID:D011851] Renal Cell Carcinoma[MeSHID:D002292] Thyroid carcinoma[MeSHID:D013964] Neoplasm Metastasis[MeSHID:D009362] Cell Differentiation process[MeSHID:D002454] Liver carcinoma[MeSHID:D006528] Recurrence (disease attribute)[MeSHID:D012008] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] melanoma[MeSHID:D008545] Malignant Neoplasms[MeSHID:D009369] Malignant neoplasm of ovary[MeSHID:D010051] Non-Small Cell Lung Carcinoma[MeSHID:D002289] |
NA | approved,investigational | inhibitor |
| lenvatinib | vascular endothelial growth factor receptor 1 | small molecule | NA | drugbank , DGIDB | Thyroid Gland[MeSHID:D013961] Disease[MeSHID:D004194] Radioactivity[MeSHID:D011851] Renal Cell Carcinoma[MeSHID:D002292] Thyroid carcinoma[MeSHID:D013964] Neoplasm Metastasis[MeSHID:D009362] Cell Differentiation process[MeSHID:D002454] Liver carcinoma[MeSHID:D006528] Recurrence (disease attribute)[MeSHID:D012008] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] melanoma[MeSHID:D008545] Malignant Neoplasms[MeSHID:D009369] Malignant neoplasm of ovary[MeSHID:D010051] Non-Small Cell Lung Carcinoma[MeSHID:D002289] |
0.19 | approved,investigational | inhibitor |
| lenvatinib | vascular endothelial growth factor receptor 3 | small molecule | NA | drugbank , DGIDB | Thyroid Gland[MeSHID:D013961] Disease[MeSHID:D004194] Radioactivity[MeSHID:D011851] Renal Cell Carcinoma[MeSHID:D002292] Thyroid carcinoma[MeSHID:D013964] Neoplasm Metastasis[MeSHID:D009362] Cell Differentiation process[MeSHID:D002454] Liver carcinoma[MeSHID:D006528] Recurrence (disease attribute)[MeSHID:D012008] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] melanoma[MeSHID:D008545] Malignant Neoplasms[MeSHID:D009369] Malignant neoplasm of ovary[MeSHID:D010051] Non-Small Cell Lung Carcinoma[MeSHID:D002289] |
0.3 | approved,investigational | inhibitor |
| lenvatinib | vascular endothelial growth factor receptor 2 | small molecule | Successful target | TTD , drugbank , DGIDB | Thyroid Gland[MeSHID:D013961] Disease[MeSHID:D004194] Radioactivity[MeSHID:D011851] Renal Cell Carcinoma[MeSHID:D002292] Thyroid carcinoma[MeSHID:D013964] Neoplasm Metastasis[MeSHID:D009362] Cell Differentiation process[MeSHID:D002454] Liver carcinoma[MeSHID:D006528] Recurrence (disease attribute)[MeSHID:D012008] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] melanoma[MeSHID:D008545] Malignant Neoplasms[MeSHID:D009369] Malignant neoplasm of ovary[MeSHID:D010051] Non-Small Cell Lung Carcinoma[MeSHID:D002289] |
0.23 | approved,investigational | inhibitor |
| lenvatinib | mast/stem cell growth factor receptor kit | small molecule | NA | drugbank , DGIDB | Thyroid Gland[MeSHID:D013961] Disease[MeSHID:D004194] Radioactivity[MeSHID:D011851] Renal Cell Carcinoma[MeSHID:D002292] Thyroid carcinoma[MeSHID:D013964] Neoplasm Metastasis[MeSHID:D009362] Cell Differentiation process[MeSHID:D002454] Liver carcinoma[MeSHID:D006528] Recurrence (disease attribute)[MeSHID:D012008] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] melanoma[MeSHID:D008545] Malignant Neoplasms[MeSHID:D009369] Malignant neoplasm of ovary[MeSHID:D010051] Non-Small Cell Lung Carcinoma[MeSHID:D002289] |
0.15 | approved,investigational | inhibitor |
| lenvatinib | platelet-derived growth factor receptor alpha | small molecule | NA | drugbank , DGIDB | Thyroid Gland[MeSHID:D013961] Disease[MeSHID:D004194] Radioactivity[MeSHID:D011851] Renal Cell Carcinoma[MeSHID:D002292] Thyroid carcinoma[MeSHID:D013964] Neoplasm Metastasis[MeSHID:D009362] Cell Differentiation process[MeSHID:D002454] Liver carcinoma[MeSHID:D006528] Recurrence (disease attribute)[MeSHID:D012008] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] melanoma[MeSHID:D008545] Malignant Neoplasms[MeSHID:D009369] Malignant neoplasm of ovary[MeSHID:D010051] Non-Small Cell Lung Carcinoma[MeSHID:D002289] |
0.16 | approved,investigational | inhibitor |
| lenvatinib | proto-oncogene tyrosine-protein kinase receptor ret | small molecule | NA | drugbank , DGIDB | Thyroid Gland[MeSHID:D013961] Disease[MeSHID:D004194] Radioactivity[MeSHID:D011851] Renal Cell Carcinoma[MeSHID:D002292] Thyroid carcinoma[MeSHID:D013964] Neoplasm Metastasis[MeSHID:D009362] Cell Differentiation process[MeSHID:D002454] Liver carcinoma[MeSHID:D006528] Recurrence (disease attribute)[MeSHID:D012008] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] melanoma[MeSHID:D008545] Malignant Neoplasms[MeSHID:D009369] Malignant neoplasm of ovary[MeSHID:D010051] Non-Small Cell Lung Carcinoma[MeSHID:D002289] |
0.48 | approved,investigational | inhibitor |
| click here to return to the previous page | ||||||||